On Tuesday, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) opened lower -0.48% from the last session, before settling in for the closing price of $39.61. Price fluctuations for RARE have ranged from $29.59 to $60.37 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 2.45%. Company’s average yearly earnings per share was noted 18.09% at the time writing. With a float of $88.38 million, this company’s outstanding shares have now reached $93.74 million.
The extent of productivity of a business whose workforce counts for 1294 workers is very important to gauge. In terms of profitability, gross margin is 83.63%, operating margin of -86.94%, and the pretax margin is -92.63%.
Ultragenyx Pharmaceutical Inc (RARE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.52%, while institutional ownership is 95.29%. The most recent insider transaction that took place on Jun 20 ’25, was worth 89,923. In this transaction Director of this company sold 2,405 shares at a rate of $37.39, taking the stock ownership to the 15,344 shares. Before that another transaction happened on Jun 20 ’25, when Company’s Director proposed sale 2,405 for $37.39, making the entire transaction worth $89,923.
Ultragenyx Pharmaceutical Inc (RARE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 18.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 65.39% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Check out the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). In the past quarter, the stock posted a quick ratio of 2.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.88, a number that is poised to hit -1.30 in the next quarter and is forecasted to reach -3.44 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
The latest stats from [Ultragenyx Pharmaceutical Inc, RARE] show that its last 5-days average volume of 1.1 million was superior to 0.95 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 91.72%.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 58.93%, which indicates a significant decrease from 85.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.44 in the past 14 days, which was lower than the 1.65 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.83, while its 200-day Moving Average is $43.07. Now, the first resistance to watch is $39.95. This is followed by the second major resistance level at $40.49. The third major resistance level sits at $40.87. If the price goes on to break the first support level at $39.04, it is likely to go to the next support level at $38.66. The third support level lies at $38.12 if the price breaches the second support level.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
There are currently 94,542K shares outstanding in the company with a market cap of 3.73 billion. Presently, the company’s annual sales total 560,230 K according to its annual income of -569,180 K. Last quarter, the company’s sales amounted to 139,290 K and its income totaled -151,080 K.
